Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Depatuxizumab mafodotin
Другие языки:

    Depatuxizumab mafodotin

    Подписчиков: 0, рейтинг: 0
    Depatuxizumab mafodotin
    Mafodotin ADCs.svg
    Monoclonal antibody
    Type Whole antibody
    Source Chimeric/humanized hybrid (mouse/human)
    Target EGFR
    Clinical data
    Other names ABT-414
    ATC code
    • none
    Identifiers
    CAS Number
    ChemSpider
    • none
    UNII
    KEGG
    Chemical and physical data
    Formula C6624H10228N1728O2052S42
    Molar mass 148251.25 g·mol−1

    Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

    This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.

    In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme. It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors. Phase I results were presented at ASCO in 2016.


    Новое сообщение